A group of international lung cancer experts is seeking comments for the evidence-based guidelines of “Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors” (J Thorac Oncol. 2013 Oct 8(10):1343; PMID:23552377)
The comment period began on June 28, 2016, and will end on Aug. 2. The research group is a collaboration of the College of American Pathologists, Association for Molecular Pathology (AMP) and International Association for